london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Effect of oral supplementation with docosahexaenoic acid (DHA) in self-reported vision-targeted healh status in patients with diabetic macular edema (DME) treated with intravitreal (IV) ranibizumab

Poster Details

First Author: M.Lafuente SPAIN

Co Author(s):    J.L. Guindo   M. Argente   L. Ortín   J. Lajara   F. Fenoy   D. López Bernal   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the effect of oral supplementation with DHA on self-reported vision health status in diabetic patients suffering from macular edema treated with IV ranibizumab.

Setting:

A total of 63 diabetic patients with DME where included in the study. All patients were treated with IV ranibizumab. 27 of them were also given DHA.

Methods:

All patients were treated with monthly intraviteal Ranibizumab (0.05mg) the first four months and then revised monthly and treated on an as-needed (PRN) basis. 27 patients received an additional oral suplementation with DHA (1500 mg/day). The patients were tested using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) at the beginning of the study, and retested six and twelve months later. The questionnaire was divided in four parts: sight and general health, difficulty in sight activities in general, how to face sight problems and difficulty in short distance activities.

Results:

All patients felt a significant improvement at the end of the treatment in sight and general health, difficulty in sight activities in general and difficulty in short distance activities. DHA supplementation did not enhance the effects of ranibizumab.

Conclusions:

It cannot be concluded that oral supplementation with DHA has additional beneficial effects in diabetic patients with macular edema treated with intravitreal ranibizumab.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy